Discover Pharma

21/11/2025

🎄 Our 12 Days of Christmas Deal Is Exploding… Don’t Miss Out! 🎄

We knew our 12 Days of Christmas launch would be popular — but we’ve been absolutely inundated with sign-ups since it went live. If you’ve been thinking about jumping in, now’s the moment.

Spaces are already filling far faster than we expected (December chaos is real), and once they’re gone… they’re gone.

If you want to lock in the offer everyone’s talking about — and secure something to look forward to before the holiday madness truly hits — grab your spot now. ✨ Treat yourself. Beat the rush. Don’t miss your chance.

And here's some recent metrics to prove how well we're doing 😎 and how far we've come, which is a long way since April. Read on if you need convincing 🙃

Website Audience

Total Page Views: 1.4K
Active Users: 1.4K
Top Countries: UK, US, Sweden, India

High-engagement pages available for sponsored content

LinkedIn Audience
Impressions: 4.1K
Engagement Rate (Top Post): 122%
Top posts available for sponsored campaigns
Top Content Opportunities for Sponsorship (and really reasonable rates)

Website: https://lnkd.in/ejRVz7vh – Connecting people with science (3001 views)

LinkedIn: 12 Days of Christmas campaign (122% engagement)
Industry-focused articles and campaigns across pharma and biotech topics

Multi-Channel Reach

Combining website and LinkedIn ensures your message reaches active, engaged life sciences professionals across key global markets.
Opportunities include sponsored posts, banner placements, and content collaborations.

Why Advertise With Discover Pharma

Direct access to highly engaged audiences in pharma, biotech, and life sciences

Demonstrated global reach with strong engagement metrics

Flexible sponsorship options for website, social, and content campaigns

Advertise With Us Today!

Email: alex@discover-pharma.com

Website: www.discover-pharma.com

17/11/2025

https://mailchi.mp/83a1f8d15947/from-blood-cancer-treatments-to-ai-driven-cell-models-this-weeks-pharma-highlights

Here's our latest newsletter - don't forget to sign up if you haven't already! There's a box on our homepage on the right hand side and I'll leave a link in the comments!

Hello and welcome to this week’s edition of the Discover Pharma newsletter. It’s been a busy week in life sciences, with major developments across oncology, immunology, AI‑driven drug discovery, and rare diseases.

17/11/2025

🎄 The 12 Days of Christmas are coming to Discover Pharma!

Get ready for a festive countdown featuring insights from across the pharma world. Reflections, predictions, and a touch of holiday cheer — watch this space!

If you can't wait any longer, email Alexandra: alex@discover-pharma.com and she will send you the full details 😁

12/11/2025

https://mailchi.mp/b70af1e2e090/recently-travelled-but-back-with-six-pharma-stories

If you haven't signed up already - make sure you do - we'd hate for you to be missing out on the best pharma news....!

With trips to Lithuania, Sweden and Frankfurt, October was a whirlwind of airports, agendas and caffeine. Most in the industry will know just how colossal CPhI is, so it may come as no surprise we had a week's newsletter break - but we’re back now, and this issue is packed with smart science, shar...

09/10/2025

✨ Big moves, bigger impact. Our audience of marketing and media pros is growing fast — 1.2K website users, 16,800+ LinkedIn impressions.

🔥 This isn’t just reach — it’s reaching decision-makers who engage, share, and act. Don’t just watch — join the conversation.

✨ Let’s put your brand in front of the right eyes. Contact Alexandra at alex@discover-pharma.com for a copy of our full stats report - and to find out about our amazing and competitive deals!

01/10/2025

https://discover-pharma.com/spotitearly-and-hackensack-meridian-health-partner-to-advance-early-detection-with-trained-dogs/

SpotitEarly has teamed up with Hackensack Meridian Health to explore innovative ways to detect cancer early using trained dogs and AI. 🐶💡

The collaboration launches the PINK Study, a 2,000-participant trial starting with breast cancer and expanding to other cancers in the future. The study combines canine scent detection with SpotitEarly’s LUCID AI platform to identify cancer odor signatures in breath samples, offering a potentially more accessible way to screen for disease.

“Less than 15 percent of all cancers in the US are diagnosed through a recommended screening protocol. This number is far too low,” said Shlomi Madar, CEO of SpotitEarly.

Early detection can save lives — and this partnership could be a step toward making screening easier and more accurate.

29/09/2025

💊💸 $181 billion in potential savings — here’s how new legislation could make medicines more affordable!

Bipartisan legislation introduced by Representatives Pfluger (R-TX) and Landsman (D-OH) 🏛️ aims to cut red tape ✂️ and speed up access to lower-cost biosimilars for American patients.

🗣️ Juliana M. Reed, executive director of the Biosimilars Forum, said: “This legislation aligns with current scientific evidence and regulatory practices, ensuring that patients benefit from the cost savings and expanded treatment options that biosimilars offer.”

With a looming ‘biosimilars void’ ⚠️, now is the time to make sure patients can access affordable biologic medicines 💉💡.

👉 Full story: https://discover-pharma.com/biosimilars-forum-highlights-181-billion-in-potential-savings-as-lawmakers-push-for-lower-cost-medicines/

Proposed legislation aims to streamline biosimilar development and expand patient access Representatives August Pfluger (R-TX) and Greg Landsman (D-OH) have introduced legislation aimed at reducing regulatory barriers and expanding access to affordable biosimilars for American patients. The bill see...

27/09/2025

🎯 A new option for patients with neuroendocrine tumours (NETs) in the UK!

The MHRA has approved cabozantinib, developed by Ipsen, for adults with unresectable or metastatic NETs whose disease progressed after prior therapy.

Key points:

First licensed systemic therapy in the UK for previously treated NETs

Phase 3 CABINET trial showed strong improvements in progression-free survival

Safety profile aligned with expectations, quality of life maintained

🔗 Learn more: https://discover-pharma.com/4917-2/

💬 Discussion: How do you see new systemic therapies shaping rare cancer treatment in the UK?

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for cabozantinib Ipsen (cabozantinib) in adults with unresectable or metastatic neuroendocrine tumours (NETs) whose disease has progressed after at least one prior systemic therapy. This approval ma...

27/09/2025

💡 BMS is taking customer engagement to the next level!

Bristol Myers Squibb is now using Veeva Vault CRM with embedded AI to streamline medical and commercial interactions. Think predictive analytics, personalized outreach, and smarter, data-driven decisions — all in a regulated cloud platform built for pharma.

Why it matters:

AI-powered insights embedded directly in CRM

Scalable, secure Vault cloud architecture

Optimized engagement for sales, medical affairs, and commercial teams

🔗 Full story: https://discover-pharma.com/bristol-myers-squibb-adopts-veeva-vault-crm-with-embedded-ai/

💬 Your thoughts: How do you see AI changing pharma CRM in the next few years?

Bristol Myers Squibb (BMS) has committed to Veeva Vault CRM in a move designed to transform how the company engages with healthcare professionals and supports patient care through embedded artificial intelligence. The announcement, made by Veeva Systems, marks the next step in a long-standing partne...

27/09/2025

🚀 Precision oncology is getting smarter!

Inaphaea BioLabs is taking a huge leap with new partnerships, advanced tumour models, and digital patient avatars — all designed to make cancer drug development faster, safer, and more precise.

Highlights:

Strategic collaborations with Dominion Biotech and Stingray Bio

Patient-derived cancer models & 3D tumour analytics

Digital patient avatars for biomarker discovery and trial simulation

Expanded drug repositioning pipeline across multiple cancer types

This is what happens when AI, digital modelling, and translational oncology come together. 💡

🔗 Read more: https://discover-pharma.com/inaphaea-biolabs-boosts-precision-oncology-with-new-partnerships-advanced-tumour-models-and-digital-patient-avatars/

💬 Question for you: Which digital tools do you think will have the biggest impact on cancer research in the next 5 years?

Inaphaea BioLabs, the translational contract research organisation (CRO) of ValiRx Plc, is accelerating precision oncology research through a series of strategic collaborations, expanded patient-derived cancer models, and enhanced digital drug discovery capabilities. The initiatives aim to streamlin...

23/09/2025

https://discover-pharma.com/lithuanias-vice-minister-daniel-naumovas-on-health-innovation-we-want-patients-to-feel-they-can-get-the-best-treatment-here/

This is one inspiring young man - Lithuania's vice president of health, Daniel Naumovas. He is determined to get the best healthcare for his country while making the world sit up and take notice.

Read our interview here:

Daniel Naumovas is a scientist, a teacher and, at 31, Lithuania’s vice minister of health with responsibility for innovation. During Life Sciences Baltic, 2025, Discover Pharma had the pleasure of speaking with him - his energy is infectious. When Naumovas talks about health policy, his words come...

23/09/2025

🌟 What a month for our community!

Our content is reaching more people than ever — from the US and UK to Sweden, India, Germany, and beyond!

We’ve seen amazing growth on both our website and LinkedIn, and it’s all thanks to YOU, our engaged and curious audience. Every click, comment, and share helps our community grow — and we couldn’t do it without you. 💙

Here’s a snapshot of the action:

Website visitors up 44%

New users up 39%

LinkedIn impressions up over 10x!

Let’s keep the conversation going — we can’t wait to share what’s next.